MARK1 and neoplasm: We embedded LKB1-null H157 tumor spheroids in a 2 mg/ml collagen gel for the following conditions: LKB1WT (wild type, Fig. 5a), Empty GFP (LKB1-null, Fig. 5b), LKB1CTD (deletion mutation and contains only C-terminal domain of LKB1, Fig. 5c), LKB1C430S (point mutation at farnesylation domain of LKB1, Fig. 6a), LKB1K78I (a point mutation in the kinase domain of LKB1, Fig. 6b), LKB1K78I+C430S (double mutations at kinase and farnesylation domain of LKB1, Fig. 6c), LKB1WT + siRNActrl (siRNA with no target, Fig. 7a), and LKB1WT + siRNAMARK1 (siRNA targeting MARK1, Fig. 7b).